Tempus AI (NASDAQ:TEM) Trading Up 13.1% – Time to Buy?

Tempus AI, Inc. (NASDAQ:TEM) was up 13.1% during trading on Monday . The company traded as high as $57.69 and last traded at $58.10. Approximately 6,508,913 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 13,653,986 shares. The stock had previously closed at $51.35.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TEM. William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Needham & Company LLC lifted their target price on shares of Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Bank of America increased their price target on shares of Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. Guggenheim restated a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Finally, Loop Capital cut their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and an average target price of $61.18.

Tempus AI Trading Down 0.7 %

The stock has a fifty day moving average of $57.42 and a 200 day moving average of $51.46. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Transactions at Tempus AI

In other news, major shareholder Bradley A. Keywell sold 170,720 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $35.45, for a total value of $6,052,024.00. Following the completion of the sale, the insider now directly owns 15,993,729 shares of the company’s stock, valued at $566,977,693.05. This represents a 1.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Ryan Fukushima sold 20,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the completion of the transaction, the chief operating officer now directly owns 982,442 shares of the company’s stock, valued at $38,914,527.62. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,598,969 shares of company stock valued at $317,194,162 over the last quarter.

Institutional Trading of Tempus AI

Several institutional investors have recently made changes to their positions in TEM. Wells Fargo & Company MN boosted its stake in Tempus AI by 13.2% in the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock worth $80,000 after purchasing an additional 278 shares during the period. First Horizon Advisors Inc. bought a new position in shares of Tempus AI during the third quarter worth $30,000. Geode Capital Management LLC grew its stake in Tempus AI by 0.4% during the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after acquiring an additional 539 shares in the last quarter. Operose Advisors LLC bought a new stake in Tempus AI in the 4th quarter valued at $25,000. Finally, Prestige Wealth Management Group LLC lifted its stake in Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.